# JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

> **NCT06731153** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 40 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ivarmacitinib
- **DRUG:** Camrelizumab (SHR-1210)
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT06731153
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731153, "JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06731153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*